At 6.1% CAGR, the Middle East & Africa Benign Prostatic Hyperplasic Devices Market is projected to be worth US$ 130.44 million by 2028, says Business Market Insights   

According to Business Market Insights’ research, the Middle East & Africa benign prostatic hyperplasic devices market was valued at US$ 91.28 million in 2022 and is expected to reach US$ 130.44 million by 2028, registering an annual growth rate of 6.1% from 2022 to 2028. Emerging markets and extending product approvals and launches.                

The benign prostatic hyperplasic devices market includes many small and big companies. Market players are adopting various strategies to increase their market shares; these include new product launches, regional expansion, and technological advancements. With continued innovation, benign prostatic hyperplasic devices are becoming safer, and treatments are becoming easier and more effective than ever. This is driving the acceptance of benign prostatic hyperplasic devices across the region. A few of the recent developments in the benign prostatic hyperplasic devices market are: In April 2020, Olympus announced the approval of iTind, its nonsurgical medical device, for the minimally invasive surgery of BPH. This is a temporarily urethral opening device that has been given a De Novo classification by the FDA and is a Class II medical device. The active participation of market players in product innovation and development, and an increase in the approvals of products are likely to fuel the growth of the benign prostatic hyperplasic devices market during the forecast period.

On the contrary, stringent awareness about prostate health among men. 

• Based on product, the Middle East & Africa benign prostatic hyperplasic devices market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment held 34.7% market share in 2022, amassing US$ 31.65 million. It is projected to garner US$ 44.77 million by 2028 to expand at 5.9% CAGR during 2022–2028.
• Based on procedure type, the Middle East & Africa benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held 28.8% market share in 2022, amassing US$ 26.32 million. It is projected to garner US$ 38.88 million by 2028 to expand at 6.7% CAGR during 2022–2028.
• Based on end user, the Middle East & Africa benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held 41.8% market share in 2022, amassing US$ 38.17 million. It is projected to garner US$ 53.99 million by 2028 to expand at 5.9% CAGR during 2022–2028
• Based on country, the Middle East & Africa benign prostatic hyperplasic devices market has been segmented into Saudi Arabia, South Africa, the UAE, and Rest of MEA.  Our regional analysis states that Saudi Arabia captured 46.0% market share in 2022. It was assessed at US$ 42.03 million in 2022 and is likely to hit US$ 59.43 million by 2028, exhibiting a CAGR of 5.9% during the forecast period.  

Key players dominating the Middle East & Africa benign prostatic hyperplasic devices market are KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; Butterfly; and ProArc among others.

• In June 2021, Olympus Corporation acquired Israeli medical device company Medi-Tate Ltd. Through this acquisition, Olympus expanded its business line in offering in-office treatment for benign prostatic hyperplasia (BPH) treatment and solidified its position as a leader in the field of urological devices.
• In June 2018, Olympus entered into a final agreement with Medi-Tate Ltd., an Israeli-based medical device manufacturer engaged in the research and development, production, and sale of devices for the treatment of Benign Prostatic Hyperplasia (BPH).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com